Johanna Oechtering, MD, University Hospital and University of Basel, Basel, Switzerland, discusses the knowledge gaps in understanding the role of the complement system in the pathogenesis and potential treatment of multiple sclerosis (MS). She mentions obstacles, including translating findings from animal models to humans, identifying specific drug targets, and getting drugs across the blood-brain barrier. This interview took place at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2024) in Copenhagen, Denmark.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.